Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

13.78 +0.28 (+2.07%)
Streaming Delayed Price Updated: 12:33 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,183
Open 13.40
Bid (Size) 13.78 (4)
Ask (Size) 13.81 (22)
Prev. Close 13.50
Today's Range 13.30 - 13.84
52wk Range 10.14 - 22.76
Shares Outstanding 58,041,410
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-13.55%
-13.55%
1 Month
-4.77%
-4.77%
3 Month
-6.89%
-6.89%
6 Month
-13.39%
-13.39%
1 Year
+27.12%
+27.12%

More News

Read More
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
Via Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
Via Benzinga
Where Deciphera Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
Via Benzinga
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Why Deciphera Pharmaceuticals Stock Jumped This Week
Via The Motley Fool
Earnings Outlook For Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
Via Benzinga
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
Via Benzinga
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.